We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

66 hedge funds and large institutions have $12.3M invested in Galectin Therapeutics in 2023 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 16 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 3

96% more call options, than puts

Call options by funds: $45K | Put options by funds: $23K

10% more funds holding

Funds holding: 60 → 66 (+6)

3.24% less ownership

Funds ownership: 15.22% → 11.98% (-3.2%)

29% less capital invested

Capital invested by funds: $17.4M → $12.3M (-$5.09M)

38% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 16

Holders
66
Holders Change
+6
Holders Change %
+10%
% of All Funds
0.96%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
10
Reduced
16
Closed
3
Calls
$45K
Puts
$23K
Net Calls
+$22K
Net Calls Change
-$21K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$360K
2
6CM
683 Capital Management
New York
+$215K
3
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$139K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$93.4K
5
Jane Street
Jane Street
New York
+$65.5K

Top Sellers

Rank Fund Capital Flow
1
Osaic Holdings
Osaic Holdings
Arizona
-$3.93M
2
Millennium Management
Millennium Management
New York
-$145K
3
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
-$108K
4
CCB
Cutter & Co Brokerage
Missouri
-$23.3K
5
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
-$22.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$3.22M – – –
Osaic Holdings
2
Osaic Holdings
Arizona
$2.08M -$3.93M -2,024,144 -62%
BlackRock
3
BlackRock
New York
$1.19M -$20.5K -10,573 -1%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$854K +$7.73K +3,985 +0.8%
GWM
5
Geneos Wealth Management
Colorado
$685K -$9.12K -4,700 -1%
Morgan Stanley
6
Morgan Stanley
New York
$615K +$360K +185,535 +100%
AWS
7
Atria Wealth Solutions
New York
$415K -$19.4K -10,000 -4%
WANY
8
Wealthspire Advisors (New York)
New York
$305K – – –
State Street
9
State Street
Massachusetts
$268K – – –
Cambridge Investment Research Advisors
10
Cambridge Investment Research Advisors
Iowa
$210K -$22.5K -11,591 -8%
CCB
11
Cutter & Co Brokerage
Missouri
$195K -$23.3K -12,000 -9%
6CM
12
683 Capital Management
New York
$184K +$215K +111,035 New
Commonwealth Equity Services
13
Commonwealth Equity Services
Massachusetts
$175K -$2.2K -1,136 -1%
Northern Trust
14
Northern Trust
Illinois
$168K -$1.83K -942 -0.9%
Susquehanna International Group
15
Susquehanna International Group
Pennsylvania
$131K +$93.4K +48,152 +155%
Qube Research & Technologies (QRT)
16
Qube Research & Technologies (QRT)
United Kingdom
$125K +$139K +71,790 +1,982%
MML Investors Services
17
MML Investors Services
Massachusetts
$90K – – –
HKAM
18
Horizon Kinetics Asset Management
New York
$89.2K -$4.38K -2,258 -4%
LPL Financial
19
LPL Financial
California
$86K – – –
SF
20
Synovus Financial
Georgia
$79.7K – – –
DADC
21
D.A. Davidson & Co
Montana
$70.8K +$9.37K +4,830 +13%
SWP
22
Stratos Wealth Partners
Ohio
$67.1K – – –
William Blair & Company
23
William Blair & Company
Illinois
$62.9K – – –
IAA
24
Independent Advisor Alliance
North Carolina
$59.9K – – –
S4W
25
Solutions 4 Wealth
Texas
$59.9K +$70K +36,085 New
1
2 3

GALT Hedge Fund Activity: Q4 2023 in Review

66 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q4 2023, worth a combined $12.3M — down 29% from $17.4M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new GALT positions and 3 closed out — a net gain of 6 holders — while 10 added to existing stakes and 16 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $360K. The largest seller was Osaic Holdings, cutting an estimated $3.93M.

  • 66 institutional investors held Galectin Therapeutics (GALT) as of Q4 2023, up from 60 in Q3 2023.
  • Funds reported $12.3M of Galectin Therapeutics stock for Q4 2023, down 29% quarter-over-quarter.
  • 9 funds opened new Galectin Therapeutics positions in Q4 2023 and 3 closed out, a net change of +6 holders.
  • The largest Galectin Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $360K added.
  • The largest Galectin Therapeutics seller in Q4 2023 was Osaic Holdings, an estimated $3.93M sold.

Based on aggregated 13F filings for Q4 2023.